Grünenthal today is very different compared to the start-up that was founded in 1946. A small team has grown into a workforce of 4,500 people. We have specialised to become a global leader in pain therapies. And we have transformed from a purely German business into an international organisation that offers life-changing treatments to patients in around 100 countries worldwide. That global growth has been a key factor of our success. With our strong international footprint, we can maximise our positive impact and reach as many patients as possible in our efforts to move closer towards our vision of a world free of pain.

 

In 2018, Grünenthal’s global growth took another big step forward when we created our own commercial presence in the world’s largest pharma market, the US. This country accounts for 56 percent of the world’s diagnosed neuropathic pain market, and the number of patients diagnosed with this condition in the US is expected to increase by 30 percent from 2019 to 2030¹. This exciting milestone in Grünenthal’s history of internationalisation is part of a strategic approach that has constantly gathered momentum from one decade to the next. Our 75th anniversary is a great opportunity to look back at this track record and feel excited about our plans to keep reaching more patients with life-changing medicines in the future – wherever they are in the world.